重复细针穿刺细胞学优化Afirma基因表达分类器检测甲状腺结节的选择
本研究纳入353例细胞学不确定(Bethesda III/IV)甲状腺结节患者,比较三种Afirma GEC检测策略。限制性策略仅对重复FNA仍为Bethesda III/IV的结节进行检测,可避免42个良性结节(12%)的诊断性手术,但会遗漏4例低风险癌和3例NIFTP(占检测人群2%)。
要点
- 重复FNA细胞学可指导不确定甲状腺结节是否需分子检测。
- 限制性策略特异性更高但敏感性更低,遗漏低风险肿瘤极少。
- 限制性策略可能减少良性结节的不必要诊断性手术。
核心结论
- 重复FNA细胞学可指导细胞学不确定甲状腺结节进行分子检测的选择。
- 仅对两次活检均为Bethesda III/IV的结节行Afirma GEC的限制性策略,可减少良性结节的诊断性手术,仅遗漏罕见低风险肿瘤。
主要发现
- 限制性策略会遗漏4例低风险癌和3例NIFTP(合计占检测人群2%),但避免42个良性结节(占12%)的诊断性手术。
关键数值与推荐
- 反射策略:基于初始Bethesda III/IV FNA结果即送分子检测。
- 半限制性策略:重复FNA为Bethesda I-IV时送分子检测。
- 限制性策略:仅当重复FNA仍为Bethesda III/IV时送分子检测。
临床怎么用
- 对细胞学不确定甲状腺结节,可考虑重复FNA后仅对仍为Bethesda III/IV者行Afirma GEC检测,以减少良性结节诊断性手术。
- 需权衡限制性策略遗漏低风险肿瘤的少量风险与其提高特异性的获益。
局限性
- 单中心研究,样本量有限,随访时间截至2019年12月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Molecular testing (MT) refines risk stratification for thyroid nodules that are indeterminate for cancer by fine needle aspiration (FNA) cytology. Criteria for selecting nodules for MT vary and remain largely untested, raising questions about the best strategy for maximizing the usefulness of MT while minimizing the harms of overtesting. We used a unique data set to examine the effects of repeat FNA cytology-based criteria for MT on management decisions and nodule outcomes. Methods: This was a study of adults (age 25-90 years; 281 women and 72 men) with cytologically indeterminate (Bethesda III/IV) thyroid nodules who underwent repeat FNA biopsy and Afirma Gene Expression Classifier (GEC) testing (N = 363 nodules from 353 patients) between June 2013 and October 2017 at a single institution, with follow-up data collected until December 2019. Subgroup analysis was performed based on classification of repeat FNA cytology. Outcomes of GEC testing, clinical/sonographic surveillance of unresected nodules, and histopathologic diagnoses of thyroidectomies were compared between three testing approaches: (i) Reflex (MT sent on the basis of the initial Bethesda III/IV FNA), (ii) SemiRestrictive (MT sent if repeat FNA is Bethesda I-IV), and (iii) Restrictive (MT sent only if repeat FNA is Bethesda III/IV) testing approaches. Results: Restricting MT to nodules that remain Bethesda III/IV on repeat FNA would have missed 4 low-risk cancers and 3 noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) (collectively 2% of the test population) but would have avoided diagnostic surgery for 42 benign nodules (12% of the test population). The Restrictive testing strategy was more specific (delta 0.126 confidence interval [CI 0.093 to 0.159] and 0.129 [CI 0.097 to 0.161], respectively) but less sensitive (delta -0.339 [CI -0.424 to -0.253] and -0.340 [CI -0.425 to -0.255], respectively) than the Reflex and SemiRestrictive approaches for detecting NIFTP or cancer. Conclusions: Repeat FNA cytology can guide the selection of cytologically indeterminate thyroid nodules that warrant MT. The Restrictive model of performing Afirma GEC only on nodules with two separate biopsies showing Bethesda III/IV cytology would reduce the rate of diagnostic surgery for histologically benign nodules while missing only rare low-risk tumors. Given the low but nontrivial risks of thyroidectomy, the higher specificity of the Restrictive testing approach disproportionately outweighs the potential harms.
引用
- Nishino M, Mateo R, Kilim H, et al. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing. Thyroid. 2021. PMID: 33813868. doi:10.1089/thy.2020.0969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。